Markets:

Overview

News

Currencies

International

Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

70.39 -0.80 (-1.12%)

Streaming Delayed Price Updated: 2:53 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Halozyme Therapeutics Inc (NASDAQ:HALO) Shows Strong Technical and Fundamental Momentum ↗

Today 6:01 EST

Halozyme (HALO) stock shows a powerful uptrend with strong technicals and high-growth fundamentals, including surging earnings and sales.

Via Chartmill

Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? ↗

November 12, 2025

Halozyme also boasts a 98 Composite Rating out of 99. The best growth stocks have a Composite of 90 or better.

Via Investor's Business Daily

Halozyme Therapeutics Inc (NASDAQ:HALO) Shows Strong Growth and Technical Breakout Potential ↗

November 11, 2025

Discover Halozyme (HALO), a biotech stock with strong EPS growth, high profitability, and a bullish technical breakout pattern for potential gains.

Via Chartmill

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Via MarketMinute

Topics Intellectual Property

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look ↗

November 05, 2025

Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look

Via The Motley Fool

Topics Regulatory Compliance

Halozyme (HALO) Q3 2025 Earnings Call Transcript ↗

November 03, 2025

Halozyme (HALO) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Insights into Halozyme Therapeutics's Upcoming Earnings ↗

October 31, 2025

Via Benzinga

Halozyme Therapeutics Inc (NASDAQ:HALO) Fits a Proven Growth Investing Method ↗

October 30, 2025

Halozyme Therapeutics shows strong growth metrics, including soaring earnings, sales, and a high ROE, fitting a proven growth investing strategy.

Via Chartmill

Koa Wealth Liquidates All 68K IIPR Shares Valued at $3.8 Million ↗

October 29, 2025

Koa Wealth Liquidates All 68K IIPR Shares Valued at $3.8 Million

Via The Motley Fool

Topics Cannabis

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Combines Strong Growth Momentum with Technical Breakout Setup ↗

October 27, 2025

Halozyme Therapeutics (HALO) offers a high-growth momentum play with strong earnings, rising profit margins, and a technical breakout setup for potential entry.

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗

October 25, 2025

Halozyme Therapeutics (HALO) is a strong value stock with high profitability, a healthy balance sheet, and solid growth, all while trading at an attractive valuation.

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Offers an Affordable Growth Profile ↗

October 21, 2025

Halozyme Therapeutics offers strong growth and profitability at an attractive valuation. Its ENHANZE drug delivery tech drives revenue, with a low P/E ratio for an affordable growth stock.

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO): A Growth Stock Poised for a Breakout ↗

October 18, 2025

Halozyme Therapeutics offers strong growth with high profitability and a positive technical setup, making it a compelling biotech stock to watch.

Via Chartmill

The Analyst Verdict: Halozyme Therapeutics In The Eyes Of 10 Experts ↗

October 15, 2025

Via Benzinga

Halozyme Therapeutics Inc (NASDAQ:HALO) Demonstrates Strong Growth and Profitability ↗

October 09, 2025

Discover Halozyme Therapeutics, a top growth stock with strong earnings, soaring revenue, and high profitability. A prime example of the Navellier investing method.

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO): A Prime Candidate for Affordable Growth ↗

September 26, 2025

Halozyme Therapeutics (HALO) offers strong growth, high profitability, and an attractive valuation, making it a compelling GARP (Growth at a Reasonable Price) investment candidate.

Via Chartmill

Forecasting The Future: 7 Analyst Projections For Halozyme Therapeutics ↗

September 22, 2025

Via Benzinga

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a High-Growth Momentum and Technical Breakout Opportunity ↗

September 20, 2025

Halozyme Therapeutics is a high-growth biotech stock with strong earnings, revenue momentum, and a bullish technical setup nearing a breakout.

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Embodies Navellier's Growth Investing Principles ↗

September 17, 2025

Discover Halozyme (HALO), a top growth stock with strong earnings surprises, soaring revenue, and exceptional profitability, fitting Navellier's proven investment strategy.

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Case for Value Investors ↗

September 15, 2025

Halozyme (HALO) presents a strong value investing case with low P/E ratios, robust financial health, high profitability, and solid growth, suggesting it trades below its intrinsic value.

Via Chartmill

United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results ↗

September 10, 2025

United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one.

Via Investor's Business Daily

Topics ETFs

Halozyme Therapeutics Inc (NASDAQ:HALO) Fits Minervini's Trend Template with Strong Technicals and Earnings Momentum ↗

September 09, 2025

Halozyme Therapeutics (HALO) exemplifies Mark Minervini's Trend Template, combining a strong technical uptrend with accelerating earnings growth and expanding profit margins.

Via Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Offers Affordable Growth With Strong Fundamentals ↗

September 05, 2025

Discover HALOZYME (HALO), an affordable growth stock with strong profitability, solid financials, and a reasonable valuation.

Via Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Stands Out in Navellier's Growth Screen ↗

August 27, 2025

HALOZYME (HALO) exemplifies Louis Navellier's growth investing strategy with strong sales growth, soaring earnings, high ROE, and consistent positive earnings surprises.

Via Chartmill

Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded ↗

August 26, 2025

Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday.

Via Investor's Business Daily

Topics ETFs

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Stands Out as a Top Undervalued Stock with Strong Fundamentals ↗

August 20, 2025

Discover HALOZYME (HALO), a top value investing pick. It boasts a strong Valuation Rating of 9, high profitability, and robust growth, making it a fundamentally sound yet undervalued stock.

Via Chartmill

What 7 Analyst Ratings Have To Say About Halozyme Therapeutics ↗

August 18, 2025

Via Benzinga

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Top Pick for Affordable Growth Investors ↗

August 15, 2025

HALOZYME THERAPEUTICS (HALO) offers affordable growth with strong revenue, EPS expansion, and undervalued metrics, blending value and growth investing principles.

Via Chartmill

What Does the Market Think About Halozyme Therapeutics? ↗

August 07, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.